Previous Nominations of
SFS Team Recognition Award - Second Edition
Setting up a working and functioning Finance team for the new business unit within 6 months
Setting up a working and functioning Finance team for the new business unit within 6 months
Vectura Fertin Pharma (VFP) is an integral part of PMI disruptive vision to create a smoke-free future.
At Vectura Fertin Pharma, we are reimagining Wellness and Healthcare and are driven by the exciting and unique goal of revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.
Vectura Fertin Pharma brings together Vectura’s expertise in inhalation and Fertin Pharma’s leadership in oral and intra-oral delivery systems to build upon products that exist today and make them better for consumers and patients tomorrow.
Our Finance team that has been created in 2021 is animated by a common passion: Striving for excellence and deliver a best in class partnering to the business, everywhere, and at any point in time. This Finance team worked tirelessly over the past 12 months to achieve the following critical milestones paving the way for Vectura Fertin Pharma future strategic and operational successes:
Building, assessing and advising Vectura Fertin Pharma Leadership on pivotal strategic business cases such as Otitopics, DHE, Consumer Health and NRT;
As Establishing a Governance model overseeing key strategic business and financial decisions while providing full visibility on business choices to PMI leadership;
Setting up an international and diverse Finance team across the organization;
Developing a strong underlying business understanding allowing Vectura Fertin Pharma to deliver Budget OI, despite inflationary and other unexpected headwind affecting 2022 top line
The VFP Finance team has impressed in various ways. First of all, we had to build a team from scratch, with all new people with different backgrounds, many of them not Pharma, many new to PMI. It required adjustment from all, including a great willingness to learn, accept making mistakes and a commitment to get better every day. Second, the team impressed me by its ability to deal with ambiguity. It had to find its way in following a range of strategic instructions which were varying from “invest” to “reduce cost” and “leave alone” to “integrate”. Hence, the team had to deal with a lot of uncertainty which puts stress on people and relationships. Though I think all in all, it was well-managed and we found the right balance for building a foundation for the future.
I would also like to thank the people in Vectura and Fertin. They entered a new universe, called PMI, having its good habits (we like to help and aim for quality and precision) and behaviors which when looked from the outside could raise some initial questions (we ask a lot and have some challenges to prioritize). So “thank you” Vectura and Fertin finance folks for your patience and commitment to collaborate and commitment to reach out to the PMI community to make things work.
Finally, I would like to thank the entire PMI Finance community for your continuous support throughout the year. It was not always easy, but we ultimately found the solution. We are very much looking forward to a strong partnership in 2023 and beyond.
Members
Project Story
Our team are delighted to be nominated for the SFS Co-Pilot award. We thank you for the opportunity to introduce the W&H Finance team, and to highlight our key achievements in 2022.
Our team comprises 12 members:- Sylvain Beltzung, Alex St-Denis, Julie Le Bloa, Umar Abeer, Daniel Blaha, Catherine Tan, Philippe Eareby, Gillian Fielden, Melisa Foo with the invaluable support from our colleagues at Krakow:- Andrzej Dusza, Aneta Pieprzyk and Pawel Bartlomiejczyk.
The Wellness and Healthcare segment was established in 2022 with the acquisition of Otitopic, Vectura Group and Fertin Pharma. These newly acquired entities were merged with part of the Life Sciences team based in Neuchatel with the unique goal of building a wellness and healthcare portfolio by revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.
As part of this exciting journey, W&H finance organization was built to support PMI’s new journey into this area. During this year, the team has worked diligently and tirelessly with unwavering commitment to provide the financial transparency to the business. This has been a critical achievement for us to help inform the appropriate investment decisions to be made and steer the strategic direction of the business.
We have worked seamlessly and collaboratively with the Vectura Fertin Pharma leadership team and category teams to develop business cases for various Wellness and Healthcare proprietary pipeline assets including Asprihale (treatment for myocardial infarction), Zephyr (treatment for migraine), Consumer Health, inhalable wellness, and inhalable THC, amongst others.
Given the new setup and start up nature of the business, the team has persevered and dealt well in the midst of the many challenges encountered. Excellent progress has been made on the integration activities including the operating model set up, financial closing process, and ensuring the required controls are put in place. Furthermore, we have established effective partnerships with the Vectura and Fertin Finance organisations as we continue to enhance the financial reporting processes and develop a solid understanding of their businesses in order to deliver on our financial commitments. This year we also performed the annual goodwill impairment testing for the first time and completed the purchase price allocation exercise.
As we continue to work in a dynamic environment with many ambiguities, we have successfully brought together a team with diverse backgrounds based in different locations by fostering a culture of togetherness, curiosity, and acting as an owner with common objectives whilst ensuring we have always fun (and a laugh together
Previous Nominations of
SFS Team Recognition Award - First Edition
Setting up a working and functioning Finance team for the new business unit within 6 months
Setting up a working and functioning Finance team for the new business unit within 6 months
Vectura Fertin Pharma (VFP) is an integral part of PMI disruptive vision to create a smoke-free future.
At Vectura Fertin Pharma, we are reimagining Wellness and Healthcare and are driven by the exciting and unique goal of revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.
Vectura Fertin Pharma brings together Vectura’s expertise in inhalation and Fertin Pharma’s leadership in oral and intra-oral delivery systems to build upon products that exist today and make them better for consumers and patients tomorrow.
Our Finance team that has been created in 2021 is animated by a common passion: Striving for excellence and deliver a best in class partnering to the business, everywhere, and at any point in time. This Finance team worked tirelessly over the past 12 months to achieve the following critical milestones paving the way for Vectura Fertin Pharma future strategic and operational successes:
Building, assessing and advising Vectura Fertin Pharma Leadership on pivotal strategic business cases such as Otitopics, DHE, Consumer Health and NRT;
As Establishing a Governance model overseeing key strategic business and financial decisions while providing full visibility on business choices to PMI leadership;
Setting up an international and diverse Finance team across the organization;
Developing a strong underlying business understanding allowing Vectura Fertin Pharma to deliver Budget OI, despite inflationary and other unexpected headwind affecting 2022 top line
The VFP Finance team has impressed in various ways. First of all, we had to build a team from scratch, with all new people with different backgrounds, many of them not Pharma, many new to PMI. It required adjustment from all, including a great willingness to learn, accept making mistakes and a commitment to get better every day. Second, the team impressed me by its ability to deal with ambiguity. It had to find its way in following a range of strategic instructions which were varying from “invest” to “reduce cost” and “leave alone” to “integrate”. Hence, the team had to deal with a lot of uncertainty which puts stress on people and relationships. Though I think all in all, it was well-managed and we found the right balance for building a foundation for the future.
I would also like to thank the people in Vectura and Fertin. They entered a new universe, called PMI, having its good habits (we like to help and aim for quality and precision) and behaviors which when looked from the outside could raise some initial questions (we ask a lot and have some challenges to prioritize). So “thank you” Vectura and Fertin finance folks for your patience and commitment to collaborate and commitment to reach out to the PMI community to make things work.
Finally, I would like to thank the entire PMI Finance community for your continuous support throughout the year. It was not always easy, but we ultimately found the solution. We are very much looking forward to a strong partnership in 2023 and beyond.
Members
Project Story
Our team are delighted to be nominated for the SFS Co-Pilot award. We thank you for the opportunity to introduce the W&H Finance team, and to highlight our key achievements in 2022.
Our team comprises 12 members:- Sylvain Beltzung, Alex St-Denis, Julie Le Bloa, Umar Abeer, Daniel Blaha, Catherine Tan, Philippe Eareby, Gillian Fielden, Melisa Foo with the invaluable support from our colleagues at Krakow:- Andrzej Dusza, Aneta Pieprzyk and Pawel Bartlomiejczyk.
The Wellness and Healthcare segment was established in 2022 with the acquisition of Otitopic, Vectura Group and Fertin Pharma. These newly acquired entities were merged with part of the Life Sciences team based in Neuchatel with the unique goal of building a wellness and healthcare portfolio by revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.
As part of this exciting journey, W&H finance organization was built to support PMI’s new journey into this area. During this year, the team has worked diligently and tirelessly with unwavering commitment to provide the financial transparency to the business. This has been a critical achievement for us to help inform the appropriate investment decisions to be made and steer the strategic direction of the business.
We have worked seamlessly and collaboratively with the Vectura Fertin Pharma leadership team and category teams to develop business cases for various Wellness and Healthcare proprietary pipeline assets including Asprihale (treatment for myocardial infarction), Zephyr (treatment for migraine), Consumer Health, inhalable wellness, and inhalable THC, amongst others.
Given the new setup and start up nature of the business, the team has persevered and dealt well in the midst of the many challenges encountered. Excellent progress has been made on the integration activities including the operating model set up, financial closing process, and ensuring the required controls are put in place. Furthermore, we have established effective partnerships with the Vectura and Fertin Finance organisations as we continue to enhance the financial reporting processes and develop a solid understanding of their businesses in order to deliver on our financial commitments. This year we also performed the annual goodwill impairment testing for the first time and completed the purchase price allocation exercise.
As we continue to work in a dynamic environment with many ambiguities, we have successfully brought together a team with diverse backgrounds based in different locations by fostering a culture of togetherness, curiosity, and acting as an owner with common objectives whilst ensuring we have always fun (and a laugh together
© 2021 - Powered by IT Global Communications